ClinicalTrials.Veeva

Menu

Diagnostic Value of KL-6 in ILD

F

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Status

Unknown

Conditions

Pulmonary Fibrosis

Treatments

Diagnostic Test: KL-6 levels

Study type

Observational

Funder types

Other

Identifiers

NCT03103191
IIBSP-KLS-2016-39

Details and patient eligibility

About

KL-6 may be a useful biomarker in patients with interstitial lung disease, but there is limited information in non-Asian populations. Therefore, it is necessary to carry out studies in other populations to confirm the diagnostic values of the biomarker and its prognostic implication.

Hypothesis KL-6 may be a useful biomarker in the management of interstitial lung diseases. But it is necessary to know more about its utility in the European population.

Study Objectives:

  • To determine the concentration of KL-6 in serum of patients with pulmonary fibrosis at the time of diagnosis compared to patients without pulmonary fibrosis
  • Diagnostic yield of KL-6 in patients with pulmonary fibrosis.
  • Correlation of KL-6 values with functional and radiological parameters of disease severity at diagnosis.
  • Correlation of serum KL-6 values with the evolution of the disease.

Enrollment

250 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Subjects older than 18 years.
  2. Chronic respiratory diseases )including Fibrotic interstitial lung disease, asthma or COPD) related or not to a connective tissue disease.
  3. Acceptance of the patient to participate in the study by signing the informed consent after having discussed with the researchers the objectives, risks and potential benefits.

Exclusion criteria

  1. Absence of informed consent
  2. Psychiatric disorder or limitation of collaboration (including language, socio-cultural problem, etc.).

Trial design

250 participants in 2 patient groups

Case
Description:
* 50 subjects with fibrosing interstitial lung disease. * 50 subjects with pulmonary fibrosis secondary to collagen diseases.
Treatment:
Diagnostic Test: KL-6 levels
Control
Description:
* 75 subjects without pulmonary fibrosis but with other common respiratory diseases like asthma, COPD or bronchiectasis. * 75 subjects with collagen disease without pulmonary fibrosis.
Treatment:
Diagnostic Test: KL-6 levels

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems